OncoMatch/Clinical Trials/NCT06119685
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Is NCT06119685 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for nhl.
Treatment: IDP-023 · Rituximab · Daratumumab · Interleukin-2 · Cyclophosphamide · Fludarabine · Mesna · Isatuximab — This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Non-Hodgkin Lymphoma
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Cardiac function
Impaired cardiac function or history of clinically significant cardiac disease [excluded]
Impaired cardiac function or history of clinical significant cardiac disease.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Valkyrie Clinical Trials · Los Angeles, California
- Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center · Lake Mary, Florida
- Emory University Hospital · Atlanta, Georgia
- University of Minnesota · Minneapolis, Minnesota
- NYP/Weill Cornell Medical Center · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06119685 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages